Bacillus anthracis, Protective Antigen, Recombinant (Anthrax)
Catalog No : USB-215911
951.75€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Bacillus anthracis, Protective Antigen, Recombinant (Anthrax) | ||
|---|---|---|---|
| Catalog No | USB-215911 | ||
| Supplier’s Catalog No | 215911 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 83 | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Purified | ||
| Purity | Purified (~90%) | ||
| Form | Supplied as a lyophilized powder in 5mM HEPES, 50mM sodium chloride, pH 7.5. Reconstitute with 100ul sterile ddH2O. Handle Gently. Do not vortex. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | Purified (~90%) | ||
| Description | Bacillus anthracis is the etiological agent of anthrax. Major virulence factors produced by Bacillus anthracis are the gamma-linked, poly-D-glutamic acid capsule and an exotoxin composed of three components, protective antigen (PA), lethal factor (LF), and edema factor (EF). These proteins are not toxic separately but act in binary combinations. The complex of PA, the cell binding component, with LF, one of the enzymatic moieties, is termed “lethal toxin” and can cause death. PA and the enzymatic EF together cause skin edema. After secretion, PA is cleaved by membrane peptidases, allowing the 63kD carboxy terminal fragment to oligomerize to a heptamer. Cleavage is an essential step in exposing the binding sites for EF and LF. The assembled PA complex and associated LF or EF enters the cell through endocytosis. PA mediates the transfer of LF and EF to the cytoplasm where these enzymes recognize and proteolyze their targets. The LF component, a zinc-dependent metalloprotease, cleaves the mitogen-activated protein kinase kinase (MAPKK), impairing its function and thereby blocking the MAPK signaling pathway. EF is a calmodulin-dependent adenylate cyclase which creates in the cell excess amounts of cyclic-AMP, resulting in edema. Current research is focused on the development of an effective vaccine as well as screening for potent inhibitors of the LF enzymatic activity. Source: Recombinant protein corresponding to Bacillus anthracis Protective Antigen. Molecular Weight: ~83kD Biological Activity: Assessed in combination with LF which forms a lethal cytotoxin. The cytotoxicity of this Lethal Toxin (LT) was assessed with J774A.1 cells. When cells were treated with this lot of PA alone, no toxicity was seen at 1ug/ml. The amount of PA required to produce the expected Lethal Toxin effective concentration 50% (EC50) met specification. Recommended Dilution: For tissue culture applications, medium containing glutamine must be fresh. Ammonium ion is released when glutamine breaks down, and may prevent acidification of the endosome thereby inhibiting translocation of LF or Edema Factor (EF) into the cytosol. A stable form of glutamine must be used. Endotoxin: 0.054EU/mg (kinetic chromogenic LAL assay) Activation: In certain systems, this product may require trypsinization to generate the active C-terminal 63kD fragment. Storage and Stability: Lyophilized powder may be stored at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved